Ipsen And Day One Earlier Announced Exclusive Ex U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor
Portfolio Pulse from charles@benzinga.com
Ipsen and Day One Biopharmaceuticals have announced an exclusive ex-U.S. licensing agreement to commercialize tovorafenib for pediatric low grade glioma. Ipsen will handle regulatory and commercial activities outside the U.S., while Day One will receive an upfront payment of $111 million and up to $350 million in milestone payments.
July 25, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One Biopharmaceuticals will receive significant financial benefits from the licensing agreement with Ipsen, including $111 million upfront and up to $350 million in milestone payments, along with double-digit royalties on sales.
The financial inflow from the upfront payment and potential milestone payments, along with future royalties, is likely to positively impact Day One's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100